697300-72-4

Basic information

• Product Name: 3-BROMO-2-FLUORO-5-IODOPYRIDINE
• Synonyms: 3-BROMO-2-FLUORO-5-IODOPYRIDINE
• CAS NO: 697300-72-4
• Molecular Formula: C5H2BrFIN
• Molecular Weight: 301.8829532
• Mol File: 697300-72-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 268.4 °C at 760 mmHg
• Flash Point: 116.1 °C
• Appearance: /
• Density: 2.412 g/cm³
• Refractive Index: 1.637
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-BROMO-2-FLUORO-5-IODOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-2-FLUORO-5-IODOPYRIDINE(697300-72-4)
• EPA Substance Registry System: 3-BROMO-2-FLUORO-5-IODOPYRIDINE(697300-72-4)

Safety Data

• Hazardous Substances Data: 697300-72-4(Hazardous Substances Data)

Usage

General Description

3-Bromo-2-fluoro-5-iodopyridine is a chemical compound with the molecular formula C5H2BrFIN. It is a heterocyclic compound containing a pyridine ring with bromine, fluorine, and iodine substituents. 3-Bromo-2-fluoro-5-iodopyridine is used in organic synthesis and pharmaceutical research as a building block for the development of new molecules with potential biological activity. It has the potential to be used in the production of pharmaceuticals and agrochemicals. 3-Bromo-2-fluoro-5-iodopyridine is a highly reactive compound and should be handled with caution due to its potential health hazards.

InChI:InChI=1/C5H2BrFIN/c6-4-1-3(8)2-9-5(4)7/h1-2H

Upstream product

• 20511-12-0 2-amino-5-iodopyridine 
• 697300-73-5 2-amino-3-bromo-5-iodopyridine 

Relevant articles and documents

5-Substituted Derivatives of 6-Halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-Halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with Low Picomolar Affinity for α4β2 Nicotinic Acetylcholine Receptor and Wide Range of Lipophilicity: Potential Probes for Imaging with Positron Emission Tomography

Potential positron emission tomography (PET) ligands with low picomolar affinity at the nicotinic acetylcholine receptor (nAChR) and with lipophilicity (log D) ranging from - 1.6 to +1.5 have been synthesized. Most members of the series, which are derivatives of 5-substituted-6-halogeno-A-85380, exhibited a higher binding affinity at α4β2-nAChRs than epibatidine. An analysis, by molecular modeling, revealed an important role of the orientation of the additional heterocyclic ring on the binding affinity of the ligands with nAChRs. The existing nicotinic pharmacophore models do not accommodate this finding. Two compounds of the series, 6-[18F]fluoro-5-(pyridin-3-yl)-A-85380 ([18F]31) and 6-chloro-3-((2-(S)-azetidinyl)methoxy)-5-(2-[ 18F]fluoropyridin-5-yl)pyridine) ([18F]35), were radiolabeled with 18F. Comparison of PET data for [18F]31 and 2-[18F]FA shows the influence of lipophilicity on the binding potential. Our recent PET studies with [18F]35 demonstrated that its binding potential values in Rhesus monkey brain were ca. 2.5 times those of 2-[18F]FA. Therefore, [18F]35 and several other members of the series, when radiolabeled, will be suitable for quantitative imaging of extrathalamic nAChRs.